China Yiwu Imported Commodities Fair 2020 to Exhibit Products From 78 Countries and Regions
China Yiwu Imported Commodities Fair 2020, as a professional and market-oriented trading platform for imported commodities, will be held on November 13-16, 2020 in Yiwu, an eastern city of China, under the theme “Gather Global Merchants, Share Free Trade Opportunities”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201111005968/en/
Watch the latest video of Yiwu Imported Commodities Fair here:
https://www.facebook.com/yiwuimportfair/videos/1053171861821233/
https://www.instagram.com/p/CHehVqKHDY0/?igshid=1b48f18hh0rcz
Founded in 2012, the Fair has been continuously making breakthroughs in terms of scale, number of exhibitors and products, and effects. It is regarded as one of the first-choice platforms for overseas brands of daily consumer goods to enter the Chinese market, and is also the first UFI-certified fair for imported consumer goods in China. The exhibiting categories include household articles, maternal & child products, beauty & personal care, crafts & gifts, digital gadgets, food & beverages, liquor & wine, toys, accessories, etc.
The Fair will provide a total of 2020 standard booths with an exhibition area of 50,000 square meters, attracting nearly 1,000 companies. The Fair will present five pavilions: Quality Life Pavilion (Wine & Coffee), Asia Pavilion, Europe Pavilion, America-Oceania-Africa Pavilion, and Quality Life Pavilion (Home Decoration Materials). Exhibits are from 78 countries and regions around the world, including 41 “Belt and Road” countries such as Russia, Poland, Greece, Romania, Ukraine, Turkey, India, Malaysia, Thailand, Iran, Afghanistan, Sri Lanka, and Armenia.
During the Fair, the organizer will also introduce China’s free trade zones, bonded areas and imported commodities markets that are vital to trading business to the exhibitors and buyers. The Fair will also cooperate with domestic and foreign industry societies and form buyer delegations to promote on-site deals for exhibitors. A number of procurement meetings will take place during the Fair to connect overseas brands with domestic distributors. Meanwhile, the Fair will hold new product launch conferences to showcase innovative and quality products for enterprises.
We sincerely invite friends from all over the world to visit China Yiwu Imported Commodities Fair to be held on November 13-16. We will be happy to provide you with the most thoughtful, efficient and warm services, so that everyone can share the harvest and joy of the Fair.
For more:
Official website: http://www.importfair.cn/en
Facebook: https://www.facebook.com/yiwuimportfair/
Instagram: https://www.instagram.com/yiwu_importedfair/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005968/en/
Contact information
Chim Chen
service@yiwufair.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new